Haleon plc Form 6-K Summary
Reporting period: Month ended September 2023; filed September 28, 2023. The filing contains a director declaration and no financial statements or operating results.
Business Context
Haleon plc is a global consumer-health company with products across oral health, pain relief, respiratory health, digestive health, vitamins, minerals and supplements, and other categories. Its brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, guidance or other financial metrics.
Material Changes
Deirdre Mahlan, an independent non-executive director and Chair of Haleon’s Audit & Risk Committee, was appointed Interim President, Chief Executive Officer and Chairperson of the Board of The Duckhorn Portfolio, Inc., effective September 27, 2023. The filing states that no further information was required under UK FCA Listing Rule 9.6.14R.
Outlook, Risks and Unusual Items
The filing contains no management guidance, outlook, risk update, contingency disclosure or unusual financial item. The disclosed appointment may be relevant to assessing Ms. Mahlan’s time commitments and governance responsibilities, but the filing does not describe any effect on her Haleon role.
Investor Verification Items
- Verify whether Deirdre Mahlan continued to serve as Haleon’s independent non-executive director and Audit & Risk Committee Chair after the appointment.
- Review subsequent Haleon filings for any changes to board, committee or leadership responsibilities.
- Consult Haleon’s periodic financial reports for revenue, profitability, cash flow, leverage, liquidity and guidance information not included in this Form 6-K.